1-20 of 171
Anthony R. Mato
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Lindsey E. Roeker, Andrew D. Zelenetz, Jae H. Park, Andriy Derkach, Mark Blaine Geyer, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Bita Fakhri, Catherine C. Coombs, Victoria Falco, Gail Panton, Dianna Tyznar, Dhara Soni, Lauren Nogan, Sonia Lebowitz, Katherine Blesie, Monica Shah, Sarah Court, Christopher E. Jensen, Anthony R. Mato, Meghan C. Thompson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4657.
https://doi.org/10.1182/blood-2023-181661
Published: 2023
Journal Articles

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, John C. Byrd, Talha Munir, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Anthony R. Mato, Stephan Stilgenbauer, Thomas Fehn, Paulo Andre P. de Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Journal: Blood
Blood (2022) 140 (Supplement 1): 7050–7052.
https://doi.org/10.1182/blood-2022-157060
Published: 2022
Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Mazyar Shadman, Anthony R. Mato, Connie Lee Batlevi, Ian W. Flinn, Martin Gutierrez, Marc Uemura, Don A. Stevens, Daniel Morillo, John C. Byrd, Melanie M. Frigault, George Clemens, Xin Huang, Raquel Izumi, Harvey Wong, Renee Breed, Hermes Garban, Amy J. Johnson, Beatrix Stelte-Ludwig, Arushi Mithal, Joseph Birkett, Ahmed Hamdy, Kerry A. Rogers
Journal: Blood
Blood (2022) 140 (Supplement 1): 9454–9456.
https://doi.org/10.1182/blood-2022-167651
Published: 2022
Journal Articles

A Timelapse of Patient and Provider Care Perceptions and Educational Needs for CLL over Three Years of Tailored Educational Interventions

Tariqa Ackbarali, Susan O'Brien, Anthony R. Mato, Matthew S. Davids
Journal: Blood
Blood (2022) 140 (Supplement 1): 8056–8057.
https://doi.org/10.1182/blood-2022-167610
Published: 2022
Journal Articles

BRUIN CLL-314: A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer A. Woyach, William G. Wierda, Catherine C. Coombs, Katharine L. Lewis, John G. Gribben, Maricer P. Escalon, Matteo Ceccarelli, Xiaoling Wu, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 12427–12428.
https://doi.org/10.1182/blood-2022-157589
Published: 2022
Journal Articles

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

Skye Montoya, Jessie Bourcier, Meghan C. Thompson, Mark Noviski, May Tan, Eric Wang, Xiaoli Mi, Nivetha Brathaban, Carla Barrientos Risso, Daniel Tsai, Jordan Ye, Jacob Jahn, Gabriel Pardo, Lee Cabuhat, Ryan Notti, Alejandro Pardo, Maurizio Affer, Stephanie Yung, James Luliano, Janine Powers, Daniel W Robbins, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M. Rhodes, Andrew D. Zelenetz, Lindsey E. Roeker, Hao Lu, Adam Linley, Anthony R. Mato, Omar Abdel-Wahab, Justin Taylor
Journal: Blood
Blood (2022) 140 (Supplement 1): 1811–1813.
https://doi.org/10.1182/blood-2022-163268
Published: 2022
Journal Articles

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Meghan C. Thompson, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey L. Jensen, Nirav N. Shah, Thomas Luo, Krish Patel, Neil Bailey, Bita Fakhri, Toby A. Eyre, Paola Ghione, Joanna M. Rhodes, Andrew D. Zelenetz, Justin Taylor, Maria Lia Palomba, Kendall Meyer, Danielle Rao, Yehudit Fox, Julia H. Aronson, Sarah Court, Omar Abdel-Wahab, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 9885–9888.
https://doi.org/10.1182/blood-2022-159133
Published: 2022
Journal Articles

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Arnon P. Kater, J Christine Ye, Jose Sandoval-Sus, Mar Bellido, Jacob Haaber Christensen, Anthony R. Mato, Ann Janssens, Toshihiko Oki, Daniela Hoehn, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Herbert Eradat
Journal: Blood
Blood (2022) 140 (Supplement 1): 850–851.
https://doi.org/10.1182/blood-2022-158298
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 846–849.
https://doi.org/10.1182/blood-2022-157058
Published: 2022
Journal Articles

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

Paolo Ghia, Carolyn Owen, Jacqueline C. Barrientos, Paul M. Barr, Anthony R. Mato, Chunxue Shi, Anita Szoke, Chris Abbazio, Gabriel S. Krigsfeld, Jan A. Burger
Journal: Blood
Blood (2022) 140 (Supplement 1): 4159–4161.
https://doi.org/10.1182/blood-2022-163257
Published: 2022
Journal Articles

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4156–4158.
https://doi.org/10.1182/blood-2022-167213
Published: 2022
Journal Articles

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Nirav N. Shah, Michael L. Wang, Jennifer R. Brown, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Zinzani, Alvaro J. Alencar, Thomas Gastinne, Paolo Ghia, Nicole Lamanna, Marc Hoffmann, Manish R. Patel, Ian W. Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Marańda, Bita Fakhri, Won-Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Lindsey E. Roeker, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4127–4132.
https://doi.org/10.1182/blood-2022-159035
Published: 2022
Journal Articles

Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lindsey E. Roeker, Yi Han, Kellie J. Ryan, Anna Teschemaker, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 7025–7027.
https://doi.org/10.1182/blood-2022-163534
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Michael L. Wang, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian W. Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, Ewa Lech-Marańda, Joanna M. Rhodes, Krish Patel, Jennifer A. Woyach, Nicole Lamanna, Yucai Wang, Constantine S. Tam, John F. Seymour, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Andrew D. Zelenetz, Preetesh Jain, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo B. Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 9368–9372.
https://doi.org/10.1182/blood-2022-159425
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

M.Lia Palomba, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David John Lewis, Thomas Gastinne, Shuo Ma, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Lydia Scarfò, Talha Munir, Ewa Lech-Marańda, Marc Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael L. Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna M. Rhodes, Julie M. Vose, Matthew McKinney, James N. Gerson, Minal A. Barve, Bryone J. Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah
Journal: Blood
Blood (2022) 140 (Supplement 1): 557–560.
https://doi.org/10.1182/blood-2022-159123
Published: 2022
Journal Articles

Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry

Nilanjan Ghosh, Jeff P. Sharman, Jacqueline C. Barrientos, Danielle Brander, Meghan Gutierrez, Linda Wu, Zaina P. Qureshi, Sandhya Upasani, Maoko Naganuma, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 7047–7049.
https://doi.org/10.1182/blood-2022-155649
Published: 2022
Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Anthony R. Mato, William G. Wierda, Weiyun Z. Ai, Ian W. Flinn, Michael Tees, Manish R. Patel, Krish Patel, Susan O'Brien, David A. Bond, Lindsey E. Roeker, Tanya Siddiqi, Michael L. Wang, Clare Sun, Omar Abdel-Wahab, Amanda Schwab, May Tan, Erin Meredith, Melissa A. Gessner, Su Young Kim, Adrian Wiestner, Alexey V Danilov
Journal: Blood
Blood (2022) 140 (Supplement 1): 2329–2332.
https://doi.org/10.1182/blood-2022-164772
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Marańda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Manish R. Patel, Bita Fakhri, Chan Y. Cheah, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna M. Rhodes, Francisco Hernandez-Ilizaliturri, Pier Luigi Zinzani, Minna Balbas, Binoj Nair, Paolo B. Abada, Chunxiao Wang, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2316–2320.
https://doi.org/10.1182/blood-2022-159497
Published: 2022
Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Clinical Trials & Observations
Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, Elisabeth M. Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry Erba, Richard M. Stone, Mark Litzow, Martin Tallman, Neil E. Kay
Journal: Blood
Blood (2022) 140 (2): 112–120.
https://doi.org/10.1182/blood.2021014960
Published: 2022
Includes: Supplemental data
Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Clinical Trials & Observations
Xin Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O’Brien, Jacqueline C. Barrientos, Jose Francisco Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Harry Erba, Richard Stone, Mark R. Litzow, Martin S. Tallman, Tait D. Shanafelt, Neil E. Kay
Journal: Blood
Blood (2021) 138 (26): 2810–2827.
https://doi.org/10.1182/blood.2020010146
Published: 2021
Includes: Supplemental data